Brand Name | Status | Last Update |
---|---|---|
ebglyss | Biologic Licensing Application | 2025-02-07 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
atopic dermatitis | EFO_0000274 | D003876 | L20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | 4 | 1 | 1 | 6 |
Eczema | D004485 | — | L30.9 | — | — | 4 | 1 | 1 | 6 |
Dermatitis | D003872 | — | L30.9 | — | — | 4 | 1 | 1 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Skin manifestations | D012877 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Lebrikizumab |
INN | lebrikizumab |
Description | Lebrikizumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >4I77:H|Lebrikizumab heavy chain
QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVL
TMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESK
>4I77:L|Lebrikizumab light chain
DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTIS
SLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
PDB | 4I77 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1743035 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11914 |
UNII ID | U9JLP7V031 (ChemIDplus, GSRS) |